cytosine has been researched along with Urinary Bladder Neoplasms in 25 studies
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study was designed to compare the effects of oral bropirimine with intravesical BCG, the current standard treatment in patients with newly diagnosed bladder carcinoma in situ (CIS)." | 9.09 | Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. ( Boeminghaus, FP; Debruyne, FM; Fittipaldo, A; Hall, RR; König, M; Riggi, M; Schulman, CC; Witjes, WP; Zurlo, M, 1999) |
| "Bropirimine is an orally administered immunostimulant that has been shown to have activity against carcinoma in situ (CIS) of the bladder." | 9.08 | Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. ( Crawford, ED; Flanigan, RC; Graham, SD; Grossman, HB; Lamm, DL; Lowe, BA; Moon, TD; Morganroth, J; Peabody, JO; Sarosdy, MF; Schellhammer, PF; See, WA, 1996) |
| "Bropirimine is an oral immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract." | 9.08 | Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. ( Belldegrun, A; Benson, MC; Bihrle, W; Carroll, PR; Ellis, WJ; Hudson, MA; Manyak, MJ; Sagalowsky, AI; Sarosdy, MF; Sharkey, FE, 1998) |
| "Bropirimine has been shown to have activity against carcinoma in situ (CIS) of the bladder in a previous phase-I trial." | 8.79 | A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. ( Sarosdy, MF, 1997) |
| "To investigate efficacy and safety of bropirimine, a new orally active interferon inducer, in patients with superficial bladder cancer." | 7.70 | Bropirimine, an orally active anticancer agent for superficial bladder cancer. ( Akaza, H; Kotake, T; Machida, T, 1998) |
| "Bropirimine is an antitumor agent currently used in clinical trials on bladder cancer." | 7.69 | [In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer]. ( Eto, H; Hashimoto, M; Kamidono, S; Nomura, S; Tahara, M; Takagi, H; Takahashi, M, 1996) |
| " The study was designed to compare the effects of oral bropirimine with intravesical BCG, the current standard treatment in patients with newly diagnosed bladder carcinoma in situ (CIS)." | 5.09 | Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. ( Boeminghaus, FP; Debruyne, FM; Fittipaldo, A; Hall, RR; König, M; Riggi, M; Schulman, CC; Witjes, WP; Zurlo, M, 1999) |
| "A follow-up investigation was conducted on a Late Phase II clinical study of bropirimine for carcinoma in situ (CIS) of the bladder." | 5.09 | [Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group]. ( Akaza, H; Kagawa, S; Kotake, T; Machida, T; Okajima, E; Shimazaki, J; Tashiro, K, 1999) |
| "Bropirimine is an orally administered immunostimulant that has been shown to have activity against carcinoma in situ (CIS) of the bladder." | 5.08 | Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. ( Crawford, ED; Flanigan, RC; Graham, SD; Grossman, HB; Lamm, DL; Lowe, BA; Moon, TD; Morganroth, J; Peabody, JO; Sarosdy, MF; Schellhammer, PF; See, WA, 1996) |
| "Bropirimine is an oral immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract." | 5.08 | Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. ( Belldegrun, A; Benson, MC; Bihrle, W; Carroll, PR; Ellis, WJ; Hudson, MA; Manyak, MJ; Sagalowsky, AI; Sarosdy, MF; Sharkey, FE, 1998) |
| "Bropirimine has been shown to have activity against carcinoma in situ (CIS) of the bladder in a previous phase-I trial." | 4.79 | A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. ( Sarosdy, MF, 1997) |
| "To evaluate the anti-cancer effect of unmethylated cytosine-phosphorothioate-guanine (CpG)-containing oligodeoxynucleotides (ODNs) on human bladder cancer UM-UC-3 cells, our study was carried out." | 3.96 | CpG Oligodeoxynucleotides Induces Apoptosis of Human Bladder Cancer Cells via Caspase-3-Bax/Bcl-2-p53 Axis. ( Dong, B; Fu, X; Han, B; Luo, Y; Men, H; Meng, M; Ru, R; Tian, S; Yuan, L; Zhang, F; Zhang, S, 2020) |
| "To investigate efficacy and safety of bropirimine, a new orally active interferon inducer, in patients with superficial bladder cancer." | 3.70 | Bropirimine, an orally active anticancer agent for superficial bladder cancer. ( Akaza, H; Kotake, T; Machida, T, 1998) |
| "Bropirimine is an antitumor agent currently used in clinical trials on bladder cancer." | 3.69 | [In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer]. ( Eto, H; Hashimoto, M; Kamidono, S; Nomura, S; Tahara, M; Takagi, H; Takahashi, M, 1996) |
| " Adverse drug reactions frequently observed were influenza-like symptoms such as fever (60." | 2.68 | [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)]. ( Furue, H; Ikeda, S; Machida, T; Masaoka, T, 1997) |
| "Bladder cancer is highly recurrent after intravesical therapy, and most of the deaths from this disease are due to invasive metastasis." | 1.38 | Inorganic arsenic in drinking water accelerates N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tissue damage in mice. ( Chen, SS; Huang, CC; Lin, PY; Lin, YL; Liu, YW, 2012) |
| "Thirty to sixty percent of bladder cancer has a mutation in the tumor suppressor p53 gene, and the mutational spectrum bears unique features." | 1.31 | N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: sequence preference and the effect of C5 cytosine methylation. ( Beland, FA; Feng, Z; Hu, W; Rom, WN; Tang, MS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 15 (60.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Y | 1 |
| Fu, X | 1 |
| Ru, R | 1 |
| Han, B | 1 |
| Zhang, F | 2 |
| Yuan, L | 1 |
| Men, H | 1 |
| Zhang, S | 1 |
| Tian, S | 1 |
| Dong, B | 1 |
| Meng, M | 1 |
| Li, J | 1 |
| Xu, Y | 1 |
| Zhang, Z | 2 |
| Zhang, M | 1 |
| Li, Q | 1 |
| Lin, PY | 1 |
| Lin, YL | 1 |
| Huang, CC | 1 |
| Chen, SS | 1 |
| Liu, YW | 1 |
| Schenkman, E | 1 |
| Lamm, DL | 3 |
| Perabo, FG | 1 |
| Müller, SC | 1 |
| Kassouf, W | 1 |
| Kamat, AM | 1 |
| Sarosdy, MF | 6 |
| Tahara, M | 1 |
| Nomura, S | 1 |
| Takahashi, M | 1 |
| Takagi, H | 1 |
| Hashimoto, M | 1 |
| Eto, H | 1 |
| Kamidono, S | 1 |
| Lowe, BA | 1 |
| Schellhammer, PF | 1 |
| Graham, SD | 1 |
| Grossman, HB | 1 |
| See, WA | 1 |
| Peabody, JO | 1 |
| Moon, TD | 2 |
| Flanigan, RC | 2 |
| Crawford, ED | 2 |
| Morganroth, J | 1 |
| Furue, H | 1 |
| Machida, T | 4 |
| Masaoka, T | 1 |
| Ikeda, S | 1 |
| Akaza, H | 4 |
| Shimazaki, J | 2 |
| Tashiro, K | 2 |
| Kotake, T | 3 |
| Okajima, E | 2 |
| Kagawa, S | 2 |
| Witjes, JA | 1 |
| Manyak, MJ | 1 |
| Sagalowsky, AI | 1 |
| Belldegrun, A | 1 |
| Benson, MC | 1 |
| Bihrle, W | 1 |
| Carroll, PR | 1 |
| Ellis, WJ | 1 |
| Hudson, MA | 1 |
| Sharkey, FE | 1 |
| Witjes, WP | 1 |
| König, M | 1 |
| Boeminghaus, FP | 1 |
| Hall, RR | 1 |
| Schulman, CC | 1 |
| Zurlo, M | 1 |
| Fittipaldo, A | 1 |
| Riggi, M | 1 |
| Debruyne, FM | 1 |
| Takai, D | 1 |
| Gonzales, FA | 1 |
| Tsai, YC | 1 |
| Thayer, MJ | 1 |
| Jones, PA | 1 |
| Feng, Z | 1 |
| Hu, W | 1 |
| Rom, WN | 1 |
| Beland, FA | 1 |
| Tang, MS | 1 |
| Sargent, ER | 1 |
| Williams, RD | 2 |
| Wilks, NE | 1 |
| Earhart, RH | 1 |
| Merritt, JA | 1 |
| Borden, EC | 1 |
| Sidky, YA | 1 |
| Ertürk, E | 1 |
| Wierenga, W | 1 |
| Bryan, GT | 1 |
| Del Senno, L | 1 |
| Maestri, I | 1 |
| Piva, R | 1 |
| Hanau, S | 1 |
| Reggiani, A | 1 |
| Romano, A | 1 |
| Russo, G | 1 |
| Kierum, CA | 1 |
7 reviews available for cytosine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Superficial bladder cancer therapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cyto | 2004 |
Current and new strategies in immunotherapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Administration, Oral; Antineoplastic Agents; A | 2004 |
Current state of immunotherapy for bladder cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Cytosine; Drug Admini | 2004 |
Treatment of carcinoma in situ of the urinary bladder with bropirimine.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Carcinoma in Situ; Clinical Trials as Topic; Cytosine | 1997 |
A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Carcinoma in Situ; Clinical Trials as Topic; Cytosine | 1997 |
New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Butylhydroxybutylnitrosamine; Carcinoma, Transit | 1997 |
Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Cytosine; Hemocyanins; Humans; Interferon Indu | 1992 |
7 trials available for cytosine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Bropirimine in bladder cancer: clinical studies.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Cytosine; Humans; Urinary Bladder Neoplasms | 1993 |
Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Cyt | 1996 |
[Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents; Cytosine; Drug Administration Schedule; Female; Fever; | 1997 |
[Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Topics: Administration, Oral; Anorexia; Antineoplastic Agents; Carcinoma in Situ; Cytosine; Drug Administrat | 1997 |
Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Oral; BCG Vaccine; Carcinoma in Situ; Cytosine; Humans; Remi | 1998 |
Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.
Topics: Adjuvants, Immunologic; Administration, Oral; BCG Vaccine; Carcinoma in Situ; Chi-Square Distributio | 1999 |
[Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Agents; BCG Vaccine; Carcinoma in | 1999 |
11 other studies available for cytosine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
CpG Oligodeoxynucleotides Induces Apoptosis of Human Bladder Cancer Cells via Caspase-3-Bax/Bcl-2-p53 Axis.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell Line, Tumo | 2020 |
[Expression and clinical significance of 5hmC in bladder urothelial carcinoma].
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Transitional Cell; C | 2016 |
Inorganic arsenic in drinking water accelerates N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tissue damage in mice.
Topics: Animals; Antioxidants; Arsenites; Blotting, Western; Body Weight; Butylhydroxybutylnitrosamine; Coca | 2012 |
[In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer].
Topics: Animals; Antineoplastic Agents; Cell Division; Cytosine; Humans; Mice; Mice, Inbred BALB C; Mice, In | 1996 |
Bropirimine, an orally active anticancer agent for superficial bladder cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; | 1998 |
Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer.
Topics: Alleles; Animals; Binding Sites; CCCTC-Binding Factor; Cell Line; Cytosine; DNA Methylation; DNA-Bin | 2001 |
N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: sequence preference and the effect of C5 cytosine methylation.
Topics: Aminobiphenyl Compounds; Base Sequence; Binding Sites; Carcinogens; CpG Islands; Cytosine; DNA Adduc | 2002 |
Phase 1 trial of oral bropirimine in superficial bladder cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Tra | 1992 |
Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cytosine; Drug Evaluation, Preclinical | 1990 |
Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades.
Topics: 5-Methylcytosine; Autoradiography; Blotting, Southern; Carcinoma, Transitional Cell; Cytosine; DNA, | 1989 |
Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone.
Topics: Animals; BCG Vaccine; Cell Line; Cell Survival; Cytosine; Cytotoxicity, Immunologic; Female; Interfe | 1989 |